Evidence map›Paper›PMID 32552705›Full record

ArticleBMC cancer2020

Multi-nanolayer drug delivery using radiofrequency plasma technology.

Iman Al Dybiat, Alibi Baitukha, Cynthia Pimpie, Rachid Kaci, Marc Pocard, Farzaneh Arefi Khonsari, Massoud Mirshahi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Iman Al DybiatCAP-Paris Tech, INSERM U1275, Department of Oncologic & Digestive Surgery, Université de Paris, Lariboisière Hospital, 2 rue Ambroise Paré, 75010, Paris, France.
Alibi BaitukhaLaboratoire Interfaces et Systèmes Electrochimiques, Sorbonne Universités, University Paris 06, CNRS, 4 place Jussieu, 75005, Paris, France.
Cynthia PimpieCAP-Paris Tech, INSERM U1275, Department of Oncologic & Digestive Surgery, Université de Paris, Lariboisière Hospital, 2 rue Ambroise Paré, 75010, Paris, France.
Rachid KaciCentral Department of Anatomy and Pathological Cytology, Hospital Lariboisière, 75010, Paris, France.
Marc PocardCAP-Paris Tech, INSERM U1275, Department of Oncologic & Digestive Surgery, Université de Paris, Lariboisière Hospital, 2 rue Ambroise Paré, 75010, Paris, France.
Farzaneh Arefi KhonsariLaboratoire Interfaces et Systèmes Electrochimiques, Sorbonne Universités, University Paris 06, CNRS, 4 place Jussieu, 75005, Paris, France.
Massoud MirshahiCAP-Paris Tech, INSERM U1275, Department of Oncologic & Digestive Surgery, Université de Paris, Lariboisière Hospital, 2 rue Ambroise Paré, 75010, Paris, France. massoud.mirshahi@inserm.fr.
Hôpital Lariboisière · FRInserm · FRCentre National de la Recherche Scientifique · FRLaboratoire Interfaces et Systèmes Électrochimiques · FR

Funding

National cancer Institute INCA has funded the project CORAPLAS: Controlled Release of Antineoplastic Drug from Low and Atmospheric Pressure Plasma Polymerized Biodegradable Coatings for Oncological Application. This work has been completed by the universi Project ID PC201404.
6 · The paper itself

Abstract

backgroundIt may be impossible to perform cancer surgery with free margins in the presence of an unresectable structure. Local drug treatment after surgery has been proposed to increase the rate of tumor control.

methodsMulti-nanolayers (10-330 nm) were generated by a low-pressure (375mTorr) inductively coupled plasma (13.56 MHz) reactor for anticancer drug delivery by the deposition of polycaprolactone-polyethylene glycol multistack barrier on the collagen membrane (100 μm thickness). Carboplatin (300 μg/cm

resultsThe loading of carboplatin or other drugs between the nanofilm on the collagen membrane did not modify the mesh complex architecture or the drug properties. Drugs were detectable on the membrane for more than 2 weeks in the in vitro analysis and more than 10 days in the in vivo analysis. Cytotoxic mesh decreased cell adherence (down 5.42-fold) and induced cancer cell destruction (up to 7.87-fold). Implantation of the mesh on the mouse tumor nodule modified the cell architecture and decreased the tumor size (50.26%) compared to the control by inducing cell apoptosis.

conclusionPlasma technology allows a mesh to be built with multi-nanolayer anticancer drug delivery on collagen membranes.

Indexed as

Plasma GasesAnimalsAntineoplastic AgentsApoptosisCarboplatinCell Line, TumorDrug CompoundingDrug Delivery SystemsFemaleHumansMiceNanomedicineNanostructuresNeoplasmsXenograft Model Antitumor AssaysAntineoplastic AgentsCarboplatinPlasma GasesCancerDrug deliveryFilm implantationMulti-nanolayer technologyRadio frequency plasma

Identifiers

PMID32552705
PMCPMC7302375
OpenAlexW3036752596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.